Impact BioMedical Surges to 137th in Trading Volume with 537229.72% Increase

On June 23, 2025, Impact BioMedical (IBO) experienced a significant surge in trading volume, with a turnover of 5.78 billion, marking a substantial increase of 537229.72% compared to the previous day. This surge placed Impact BioMedical at the 137th position in terms of trading volume for the day. The stock price of Impact BioMedical soared by 311.57%.

Impact BioMedical has entered into a strategic merger with Dr. Ashleys Limited. The merger, announced on June 21, 2025, aims to combine Dr. Ashleys' manufacturing capabilities and global market access with Impact BioMedical's extensive patent portfolio, which includes over 90 patents spanning various areas such as cancer treatment. The merger will result in a newly formed entity traded on the NYSE American under the name "Dr. Ashleys Limited."

Under the terms of the merger agreement, a subsidiary of Dr. Ashleys will merge with Impact BioMedical, with Impact BioMedical becoming the surviving entity. Simultaneously, Dr. Ashleys will acquire all outstanding shares of Dr. Ashleys Bio Labs Limited, a Cayman Islands exempted company holding all shares of Dr. Ashleys. Following the merger, both companies will become wholly-owned subsidiaries of the newly formed entity, which will be operated by Dr. Ashleys' management team and a new Board of Directors assembled by Dr. Ashleys.

The merger is subject to approval by Impact BioMedical's shareholders and satisfaction of various conditions, including regulatory approvals and the effectiveness of a registration statement with the U.S. Securities and Exchange Commission. The merger is expected to enhance Impact BioMedical's market reach and leverage Dr. Ashleys' global presence to drive growth and innovation in the biotechnology sector.